Ateş Ö - Search Results

1

Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.

Önder T, Ateş Ö, Öner İ, Karaçin C. Önder T, et al. Among authors: ates o. Clin Breast Cancer. 2024 Aug;24(6):519-526. doi: 10.1016/j.clbc.2024.05.004. Epub 2024 May 10. Clin Breast Cancer. 2024. PMID: 38879437

2

Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.

Karatas F, Erdem GU, Sahin S, Aytekin A, Yuce D, Sever AR, Babacan T, Ates O, Ozisik Y, Altundag K. Karatas F, et al. Among authors: ates o. Breast. 2017 Apr;32:237-244. doi: 10.1016/j.breast.2016.05.013. Epub 2016 Jun 16. Breast. 2017. PMID: 27318645

3

Vortex keratopathy associated with ribociclib.

Türkel A, Özdoğan S, Yekedüz E, Şeyran E, Karaçin C, Ateş Ö. Türkel A, et al. Among authors: ates o. J Oncol Pharm Pract. 2023 Jan;29(1):230-232. doi: 10.1177/10781552221101799. Epub 2022 May 16. J Oncol Pharm Pract. 2023. PMID: 35570741

4

HIPEC in Ovarian Cancer: When and to Whom?

Ates O, Aksel B, Akkus MH, Oner I, Yuksel C, Dogan M. Ates O, et al. J Coll Physicians Surg Pak. 2023 Sep;33(9):1001-1005. doi: 10.29271/jcpsp.2023.09.1001. J Coll Physicians Surg Pak. 2023. PMID: 37691361

5

Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients.

Erdem HB, Alay MT, Özdemir Z, Çevik E, Ateş Ö, Karaçin C, Şahin İ, Doğan M, Bahsi T. Erdem HB, et al. Among authors: ates o. Mutat Res. 2024 Jan-Jun;828:111847. doi: 10.1016/j.mrfmmm.2023.111847. Epub 2023 Nov 28. Mutat Res. 2024. PMID: 38071953

6

Prognostic factors in non-metastatic HER2 'low' and HER2 'negative' breast cancer: single institute experience.

Türkel A, Doğan M, Sertesen E, Karaçin C, Irkkan SÇ, Ateş Ö. Türkel A, et al. Among authors: ates o. Wien Klin Wochenschr. 2024 Jun;136(11-12):340-346. doi: 10.1007/s00508-023-02315-z. Epub 2024 Jan 5. Wien Klin Wochenschr. 2024. PMID: 38180508

7

Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.

Karacin C, Sunar V, Urakci Z, Yilmaz A, Ayhan M, Ersoy M, Guven DC, Erturk I, Durmus Y, Karacin P, Boran N, Ustun YE, Meydan M, Dogan M, Oksuzoğlu B, Ates O, Karaca M, Uncu D, Ergun Y, Arik Z. Karacin C, et al. Among authors: ates o. Future Oncol. 2024 Feb;20(4):207-214. doi: 10.2217/fon-2023-0763. Epub 2024 Feb 8. Future Oncol. 2024. PMID: 38328890

8

Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study.

Önder T, Ateş Ö, Öner I, Karaçin C. Önder T, et al. Among authors: ates o. Int J Clin Oncol. 2024 Jul;29(7):972-984. doi: 10.1007/s10147-024-02528-w. Epub 2024 Apr 30. Int J Clin Oncol. 2024. PMID: 38687407

9

Predicting survival after brain metastases in patients with bladder cancer.

Önder T, Karaçin C, Kekilli E, Göksel F, Sertesen E, Onur ID, Ateş Ö, Yıldız F, Arslan ÜY. Önder T, et al. Among authors: ates o. J Clin Neurosci. 2024 Jul;125:146-151. doi: 10.1016/j.jocn.2024.05.027. Epub 2024 May 28. J Clin Neurosci. 2024. PMID: 38815300

10

Effects of BRCA variation on prognosis in patients with nonmetastatic breast cancer.

Türkel A, Onur ID, Anik H, Öner I, Erdem HB, Bahsi T, Özalp Ö, Öksüzoğlu B, Ateş Ö, Karaçin C. Türkel A, et al. Among authors: ates o. Ann Hum Genet. 2024 Nov;88(6):436-444. doi: 10.1111/ahg.12577. Epub 2024 Aug 29. Ann Hum Genet. 2024. PMID: 39207234

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

357 results

Search Page

Filters